Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
393
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

438
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
438
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

2.5K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.5K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

693
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
693
Glaucoma: Overview01:25

Glaucoma: Overview

508
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
508
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary Open-Angle Glaucoma among Black and Latinx Populations: Exploring Racial Disparities in the United States.

Journal of racial and ethnic health disparities·2026
Same author

Comparison of Electroconvulsive Therapy Seizure Outcomes When Using Methohexital Versus Propofol: A Brief Retrospective Report.

The journal of ECT·2026
Same author

The impact of contact lenses on binocular vision in patients with Keratoconus.

Journal of optometry·2026
Same author

Ophthalmic manifestations in preterm children without retinopathy of prematurity: A review.

Survey of ophthalmology·2026
Same author

Early Detection of Cystoid Macular Edema in Retinitis Pigmentosa Using Longitudinal Deep Learning Analysis of OCT Scans.

Diagnostics (Basel, Switzerland)·2026
Same author

Detection of cystoid macular edema in patients with retinitis pigmentosa based on deep learning.

International journal of retina and vitreous·2025

Related Experiment Video

Updated: Jun 7, 2025

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

1.3K

Myopia Controlling using Low Dose Atropine Eye Drop.

Zhale Rajavi1,2,3, Bahareh Kheiri4,5, Kourosh Sheibani6

  • 1Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Journal of Current Ophthalmology
|November 18, 2024
PubMed
Summary

Low-dose atropine (0.01%) effectively slowed myopia progression and axial elongation in over 50% of pediatric patients over two years. This treatment is recommended for progressive myopia in children and teenagers, showing minimal complications.

Keywords:
AtropineAxial lengthLow doseMyopiaMyopic progression control

More Related Videos

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

9.8K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

370

Related Experiment Videos

Last Updated: Jun 7, 2025

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

1.3K
Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

9.8K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

370

Area of Science:

  • Ophthalmology
  • Pediatric Ophthalmology
  • Clinical Research

Background:

  • Myopia, a common refractive error, is increasing globally, particularly in children.
  • Progressive myopia poses risks for long-term ocular health, including retinal detachment and myopic maculopathy.
  • Effective interventions are crucial to slow myopia progression in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy of low-dose atropine 0.01% in managing myopia progression.
  • To assess changes in axial length, visual acuity, pupil size, and accommodation amplitude over 24 months.
  • To determine the safety and success rate of atropine 0.01% in progressive myopia.

Main Methods:

  • A prospective study involving 51 children and teenagers (3.5-17 years) with progressive myopia.
  • Treatment involved nightly instillation of atropine 0.01% in both eyes.
  • Measurements of myopic progression, axial length, visual acuity, pupil diameter, and accommodation were taken at baseline and every 6 months for 2 years.

Main Results:

  • Mean myopic progression was 0.16 D at 12 months and 1.28 D at 24 months.
  • Mean axial length increase was 0.05 mm at 12 months and 0.69 mm at 24 months.
  • The absolute success rate for myopia control was 70.8% at 24 months, with 58.3% success in controlling axial length growth.

Conclusions:

  • Atropine 0.01% significantly slows myopia progression and axial elongation in a majority of pediatric patients.
  • The treatment demonstrated a favorable safety profile with no significant complications reported.
  • Low-dose atropine therapy is a recommended and effective option for managing progressive myopia in children and adolescents.